A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ATH-063 in Healthy Subjects
Latest Information Update: 08 May 2024
At a glance
- Drugs ATH 063 (Primary)
- Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions; First in man
- Sponsors Athos Therapeutics
Most Recent Events
- 02 May 2024 Status changed from recruiting to completed.
- 30 Jan 2024 Planned End Date changed from 29 Jan 2024 to 8 Feb 2024.
- 30 Jan 2024 Planned primary completion date changed from 29 Nov 2023 to 8 Feb 2024.